Similar to the parent study, which included all consented patients, participants in each arm (rilonacept and placebo) did not differ significantly in terms of baseline characteristics including: gender, race/ethnicity, etiology of CKD, medications, smoking status, eGFR, urine protein/creatinine ratio, body-mass index, blood pressure, and serum albumin (Table 1). The gene discussed is ALB; the disease is chronic kidney disease.